Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28757237 | 0.80 | CA1 (0.30) | CA1CA2 | |
| SCHEMBL7636146 | 0.80 | ALDH1A1 (0.34) | CA1CA2 | |
| SCHEMBL2860485 | 0.80 | MEN1 (0.41) | CA1CA2 | |
| SCHEMBL29561529 | 0.80 | MEN1 (0.41) | CA1CA2 | |
| SCHEMBL22669111 | 0.74 | — | — | |
| SCHEMBL6533122 | 0.74 | NFE2L2 (0.47) | — | |
| SCHEMBL8766117 | 0.72 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL319418 | 0.72 | CYP2A6 (0.35) | CA1CA2 | |
| SCHEMBL6454972 | 0.71 | CA1 (0.35) | CA1CA2 | |
| SCHEMBL277191 | 0.70 | CA1 (0.33) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113831392-A | Method for producing drug-related peptides | 康德生物医疗技术公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-107530395-B | Method for producing drug-related peptides | 康德生物医疗技术公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210300872-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300872-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | HSP90B1, HSP90AB2P, HSPE1 | CA1 3313/4885CA2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.